Latest Esomeprazole Stories

Labeling changes will include new safety information SILVER SPRING, Md., May 25 /PRNewswire-USNewswire/ -- The U.S. Food and Drug Administration today warned consumers and health care professionals about a possible increased risk of fractures of the hip, wrist, and spine with high doses or long-term use of a class of medications called proton pump inhibitors. The product labeling will be changed to describe this possible increased risk. (Logo:...

The results of several studies released on Monday are suggesting that certain heartburn medicines may be doing more harm than good. Serious side effects could arise and it has been recommended that people use the drugs with caution. AstraZeneca's Nexium and Prilosec brands are among the drugs that could be harmful to health. While the drugs are helpful to the right patients, they can increase the risk of fractures in post-menopausal women and cause bacterial infections in many patients,...

WILMINGTON, Del., April 30 /PRNewswire-FirstCall/ -- AstraZeneca and POZEN Inc. today announced the U.S. Food and Drug Administration (FDA) has approved VIMOVO(TM)( )(naproxen and esomeprazole magnesium) delayed-release tablets for the relief of signs and symptoms of osteoarthritis, rheumatoid arthritis, and ankylosing spondylitis, and to decrease the risk of developing gastric ulcers in patients at risk of developing NSAID-associated gastric ulcers.(1) VIMOVO, co-developed by POZEN Inc....

ROCKVILLE, Md., March 15 /PRNewswire-USNewswire/ -- Heart patients who took a stomach acid-suppressing proton-pump inhibitor along with clopidogrel - a drug that prevents blood clots - were only half as likely to be hospitalized for upper digestive tract bleeding than those who used clopidogrel alone, according to a new study supported by HHS' Agency for Healthcare Research and Quality and the National Heart, Lung, and Blood Institute at the National Institutes of Health. The study also...

DEERFIELD, Ill., Feb. 9 /PRNewswire/ -- Takeda Global Research & Development Center, Inc., U.S., (TGRD U.S.) announced today that it has initiated a trial to study how dexlansoprazole and several other proton pump inhibitors (PPIs) affect the pharmacokinetics and pharmacodynamics of Plavix (clopidogrel bisulfate) in healthy subjects. Takeda has been evaluating all published data and communications from the U.S. Food and Drug Administration (FDA) regarding the potential risks associated...

The popular heartburn drugs Prilosec and Nexium can reduce by nearly half the blood thinning effect of the drug Plavix, said officials with the U.S. Food and Drug Administration (FDA) on Tuesday.Plavix, known generically as clopidogrel, is an anti-clotting drug taken by millions of Americans to reduce risks of heart attack and stroke.Nexium and Prilosec belong to a class of heartburn medications known as proton pump inhibitors (PPIs). Regulators said the key ingredient PPIs blocks an...

PHILADELPHIA, Oct. 19 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) and POZEN Inc. (Nasdaq: POZN) today announced pivotal data from two POZEN clinical trials that were presented at the American College of Rheumatology (ACR) 2009 Annual Scientific Meeting in Philadelphia, PA. The data demonstrated that patients at risk for developing NSAID-associated gastric ulcers taking VIMOVO(TM) (naproxen/esomeprazole magnesium, formerly known as PN 400) experienced significantly fewer endoscopically...

WILMINGTON, Del., June 2 /PRNewswire-FirstCall/ -- Two studies from AstraZeneca (NYSE: AZN) show that symptomatic gastroesophageal reflux disease (GERD) patients treated with NEXIUM(R) (esomeprazole magnesium) 20 mg daily experienced greater relief from nighttime heartburn and GERD-related sleep disturbances compared with patients taking placebo over four weeks(1). NEXIUM 20 mg is indicated for the treatment of heartburn and other symptoms associated with GERD. NEXIUM, in a class of drugs...

The anti-clotting action of the medication clopidogrel -- Plavix -- can be compromised by common drugs for the treatment of heartburn, U.S. researchers said. Principal investigator Eric J. Stanek of Medco Health Solutions in Franklin Lakes, N.J., said the study specifically focused on the effects of proton pump inhibitors -- omeprazole or Prilosec; esomeprazole or Nexium; pantoprazole or Protonix; and lansoprazole or Prevacid. Together those drugs accounted for about 96 percent of proton...

- Company Also Submits sNDA for NEXIUM Capsules for Risk Reduction of Low-Dose Aspirin-Associated Peptic Ulcer - WILMINGTON, Del., May 4 /PRNewswire-FirstCall/ -- AstraZeneca (NYSE: AZN) today announced the submission of a new drug application (NDA) to the U.S. Food and Drug Administration (FDA) seeking approval for a product combining low dose aspirin with esomeprazole magnesium for the risk reduction of low dose aspirin-associated gastric and/or duodenal ulcers in patients at risk....